Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07522476) titled 'A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma' on April 1.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Virogin Biotech Ltd.
Condition:
Intrahepatic Cholangiocarcinoma
Intervention:
Drug: VG2025
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: July 1, 2026
Target Sample Size: 30
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07522476
Published by HT Dig...